These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 25658233)

  • 1. [Biomarkers in metastatic castration-resistant prostate cancer].
    Miller K
    Aktuelle Urol; 2015 Jan; 46(1):66-70. PubMed ID: 25658233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating Tumor Cells as a Marker for Progression-free Survival in Metastatic Castration-naïve Prostate Cancer.
    Josefsson A; Linder A; Flondell Site D; Canesin G; Stiehm A; Anand A; Bjartell A; Damber JE; Welén K
    Prostate; 2017 Jun; 77(8):849-858. PubMed ID: 28295408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intermediate PSA half-life after neoadjuvant hormone therapy predicts reduced risk of castration-resistant prostate cancer development after radical prostatectomy.
    Kang YJ; Jang WS; Kwon JK; Yoon CY; Lee JY; Ham WS; Choi YD
    BMC Cancer; 2017 Nov; 17(1):789. PubMed ID: 29169347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AR-V7 expression in circulating tumor cells as a potential prognostic marker in metastatic hormone-sensitive prostate cancer.
    Josefsson A; Damber JE; Welén K
    Acta Oncol; 2019 Nov; 58(11):1660-1664. PubMed ID: 31286815
    [No Abstract]   [Full Text] [Related]  

  • 5. Correlation between Prostate-Specific Antigen Kinetics and Overall Survival in Abiraterone Acetate-Treated Castration-Resistant Prostate Cancer Patients.
    Xu XS; Ryan CJ; Stuyckens K; Smith MR; Saad F; Griffin TW; Park YC; Yu MK; Vermeulen A; Poggesi I; Nandy P
    Clin Cancer Res; 2015 Jul; 21(14):3170-7. PubMed ID: 25829400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostein expression on circulating tumor cells as a prognostic marker in metastatic castration-resistant prostate cancer.
    Zhang Z; Luo R; Kelly WK; Chen J; Donahue S; Ip K; Handley NR; Tester WJ; Tsang ML; Kim FJ; Myers R; Lu-Yao G; Gu J; Lin J; Li B; Wang C; Yang H
    Prostate Cancer Prostatic Dis; 2024 Jun; 27(2):339-347. PubMed ID: 38057610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.
    Azad AA; Volik SV; Wyatt AW; Haegert A; Le Bihan S; Bell RH; Anderson SA; McConeghy B; Shukin R; Bazov J; Youngren J; Paris P; Thomas G; Small EJ; Wang Y; Gleave ME; Collins CC; Chi KN
    Clin Cancer Res; 2015 May; 21(10):2315-24. PubMed ID: 25712683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Castration resistant prostate cancer 2015].
    Merseburger AS; Böker A; Kuczyk MA; von Klot CA
    Aktuelle Urol; 2015 Jan; 46(1):59-65. PubMed ID: 25658232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The predictive value of ERG protein expression for development of castration-resistant prostate cancer in hormone-naïve advanced prostate cancer treated with primary androgen deprivation therapy.
    Berg KD; Røder MA; Thomsen FB; Vainer B; Gerds TA; Brasso K; Iversen P
    Prostate; 2015 Oct; 75(14):1499-509. PubMed ID: 26053696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of prostate specific antigen pattern to predict castration resistant prostate cancer of androgen deprivation therapy.
    Kim Y; Park YH; Lee JY; Choi IY; Yu H
    BMC Med Inform Decis Mak; 2016 Jul; 16 Suppl 1(Suppl 1):63. PubMed ID: 27453983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Metastatic castration-resistant prostate cancer : Clinical data, new treatment options and therapy monitoring].
    Miller K; Albers P; Eichenauer R; Geiges G; Grimm MO; König F; Mickisch G; Pfister D; Schwentner C; Suttmann H; Zastrow S
    Urologe A; 2016 Sep; 55(9):1206-12. PubMed ID: 27411995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer.
    Bitting RL; Healy P; Halabi S; George DJ; Goodin M; Armstrong AJ
    Urol Oncol; 2015 Mar; 33(3):110.e1-9. PubMed ID: 25595577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating tumor cells as a biomarker predictive of sensitivity to docetaxel chemotherapy in patients with castration-resistant prostate cancer.
    Okegawa T; Itaya N; Hara H; Tambo M; Nutahara K
    Anticancer Res; 2014 Nov; 34(11):6705-10. PubMed ID: 25368278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current management of advanced and castration resistant prostate cancer.
    Gomella LG; Petrylak DP; Shayegan B
    Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancer.
    Friedlander TW; Ngo VT; Dong H; Premasekharan G; Weinberg V; Doty S; Zhao Q; Gilbert EG; Ryan CJ; Chen WT; Paris PL
    Int J Cancer; 2014 May; 134(10):2284-93. PubMed ID: 24166007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel prognostic markers in the serum of patients with castration-resistant prostate cancer derived from quantitative analysis of the pten conditional knockout mouse proteome.
    Kälin M; Cima I; Schiess R; Fankhauser N; Powles T; Wild P; Templeton A; Cerny T; Aebersold R; Krek W; Gillessen S
    Eur Urol; 2011 Dec; 60(6):1235-43. PubMed ID: 21741162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
    Sternberg CN; Castellano D; Daugaard G; Géczi L; Hotte SJ; Mainwaring PN; Saad F; Souza C; Tay MH; Garrido JM; Galli L; Londhe A; De Porre P; Goon B; Lee E; McGowan T; Naini V; Todd MB; Molina A; George DJ;
    Lancet Oncol; 2014 Oct; 15(11):1263-8. PubMed ID: 25242048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of circulating tumor cells in guiding treatment decisions for patients with metastatic castration-resistant prostate cancer.
    Onstenk W; de Klaver W; de Wit R; Lolkema M; Foekens J; Sleijfer S
    Cancer Treat Rev; 2016 May; 46():42-50. PubMed ID: 27107266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The utility of prostate-specific antigen in the management of advanced prostate cancer.
    Crawford ED; Bennett CL; Andriole GL; Garnick MB; Petrylak DP
    BJU Int; 2013 Sep; 112(5):548-60. PubMed ID: 23826876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current, new and novel therapy for castration-resistant prostate cancer.
    Gaya JM; Ahallal Y; Sanchez-Salas R; Barret E; Rozet F; Galiano M; Macek P; Durand M; Cerruti J; Prapotnich D; Ropert S; Bennamoun M; Cathelineau X
    Expert Rev Anticancer Ther; 2013 Jul; 13(7):819-27. PubMed ID: 23875660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.